Last updated on August 2018

A Phase 3, multicenter, randomized, double-blind, placebo-controlled study investigating the efficacy and safety of daily oral administration of OBE2109 alone and in combination with add-back therapy for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.

Brief description of study

A phase 3 study of OBE2109 in subjects with heavy menstrual bleeding associated with uterine fibroids.

Clinical Study Identifier: TX201695

Find a site near you

Start Over

IACT Health

Located in: Columbus, GA USA
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.